{
  "success": true,
  "stage": 11,
  "stage_name": "Feasibility Analysis",
  "duration_seconds": 403.4668173789978,
  "funnel_result": {
    "protocolId": "NCT05878067",
    "analysisTimestamp": "2026-02-13T14:38:41.772000",
    "isDraft": true,
    "keyCriteria": [
      {
        "keyId": "KC003",
        "category": "primary_anchor",
        "normalizedText": "Had used artificial tears for dry eyes within the past year",
        "criterionType": "Inclusion",
        "queryableStatus": "partially_queryable",
        "estimatedEliminationRate": 80.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": true,
        "funnelPriority": 1,
        "omopMappings": []
      },
      {
        "keyId": "KC001",
        "category": "primary_anchor",
        "normalizedText": "Participant must be \u2265 18 years of age",
        "criterionType": "Inclusion",
        "queryableStatus": "fully_queryable",
        "estimatedEliminationRate": 20.0,
        "requiresManualAssessment": false,
        "isKillerCriterion": true,
        "funnelPriority": 2,
        "omopMappings": []
      },
      {
        "keyId": "KC031",
        "category": "treatment_history",
        "normalizedText": "Patients who were currently using topical ocular medication or had used topical ocular medication within 2 weeks of Screening Visit; however, patients who were being treated bilaterally with the following could have been considered:\n\n\u039f Current use of a marketed artificial tear, which was to have been discontinued at the Screening Visit\n\n\u25cb Monotherapy for glaucoma or OHT using a prostaglandin analog, beta-blocker, alpha-2 agonist, or carbonic anhydrase inhibitors; any topical IOP-lowering medications must have had a start date of \u2265 3 months prior to Screening Visit and the dosage was not expected to change during the study\n\n\u039f If using any form of topical ophthalmic cyclosporine (i.e., RESTASIS\u00ae), lifitegrast 5% ophthalmic solution (Xiidra\u00ae), for less than 90 days prior to Screening Visit",
        "criterionType": "Exclusion",
        "queryableStatus": "partially_queryable",
        "estimatedEliminationRate": 30.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": true,
        "funnelPriority": 21,
        "omopMappings": []
      },
      {
        "keyId": "KC022",
        "category": "treatment_history",
        "normalizedText": "Use of systemic medications (over-the-counter, herbal, prescription, or nutritional supplements for dry eyes), which may have affected tear film or vision (including but not limited to the following: flax seed oil, fish oil, omega-3 supplements, cyclosporine, antihistamines, cholinergic agents, anticholinergics, antimuscarines, beta-blocking agents, tricyclic antidepressants, phenothiazines, estrogen-progesterone, and other estrogen derivatives), unless that medication had been used at the same dose for at least 3 months prior to screening and the dosage was not expected to change during the course of the study",
        "criterionType": "Exclusion",
        "queryableStatus": "partially_queryable",
        "estimatedEliminationRate": 20.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": true,
        "funnelPriority": 22,
        "omopMappings": []
      },
      {
        "keyId": "KC029",
        "category": "treatment_history",
        "normalizedText": "Occlusion of the lacrimal puncta for either eye, with punctal plugs or cauterization < 3 months prior to Screening Visit",
        "criterionType": "Exclusion",
        "queryableStatus": "fully_queryable",
        "estimatedEliminationRate": 12.0,
        "requiresManualAssessment": false,
        "isKillerCriterion": true,
        "funnelPriority": 23,
        "omopMappings": []
      },
      {
        "keyId": "KC032",
        "category": "treatment_history",
        "normalizedText": "Patients who were currently being treated with both IOP-lowering medication and any form of topical ophthalmic cyclosporine (i.e., RESTASIS\u00ae) or lifitegrast 5% ophthalmic solution (Xiidra\u00ae) or generic of these medications cannot be enrolled",
        "criterionType": "Exclusion",
        "queryableStatus": "fully_queryable",
        "estimatedEliminationRate": 7.0,
        "requiresManualAssessment": false,
        "isKillerCriterion": false,
        "funnelPriority": 25,
        "omopMappings": []
      },
      {
        "keyId": "KC005",
        "category": "functional",
        "normalizedText": "OSDI score of \u2265 18 and \u2264 65 (based upon a 0 to 100 scale) at Screening and Baseline Visits",
        "criterionType": "Inclusion",
        "queryableStatus": "non_queryable",
        "estimatedEliminationRate": 35.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": false,
        "funnelPriority": 31,
        "omopMappings": []
      },
      {
        "keyId": "KC006",
        "category": "functional",
        "normalizedText": "Three consecutive tear break-up time (TBUT) tests \u2264 10 seconds in at least 1 eye at Screening Visit",
        "criterionType": "Inclusion",
        "queryableStatus": "non_queryable",
        "estimatedEliminationRate": 20.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": false,
        "funnelPriority": 32,
        "omopMappings": []
      },
      {
        "keyId": "KC007",
        "category": "functional",
        "normalizedText": "Grade 1 to 4 (modified National Eye Institute [NEI] Grid, score range = 0 to 5) staining in at least 1 area of the cornea (5 areas examined) or conjunctiva (6 areas examined) that was related to dry eye in at least 1 eye at both at Screening and Baseline Visits",
        "criterionType": "Inclusion",
        "queryableStatus": "non_queryable",
        "estimatedEliminationRate": 20.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": false,
        "funnelPriority": 33,
        "omopMappings": []
      },
      {
        "keyId": "KC021",
        "category": "functional",
        "normalizedText": "At the Screening and Baseline visits, either eye has corneal staining score of 5 in any of the 5 zones or a total score of > 19 based on the modified NEI grading scheme (score range = 0 to 5; graded in 5 zones of the cornea for a total score range of 0 to 25) or conjunctival staining score of 5 in any of the 6 zones based on the modified NEI grading scheme (score range = 0 to 5 per zone)",
        "criterionType": "Exclusion",
        "queryableStatus": "non_queryable",
        "estimatedEliminationRate": 15.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": false,
        "funnelPriority": 34,
        "omopMappings": []
      },
      {
        "keyId": "KC009",
        "category": "functional",
        "normalizedText": "Currently corrected distance visual acuity of at least 20/32 Snellen equivalent in each eye using the 3-meter LogMar chart, with existing spectacle correction (if necessary) at Screening Visit",
        "criterionType": "Inclusion",
        "queryableStatus": "partially_queryable",
        "estimatedEliminationRate": 10.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": false,
        "funnelPriority": 35,
        "omopMappings": []
      },
      {
        "keyId": "KC011",
        "category": "functional",
        "normalizedText": "Intraocular pressure (IOP) \u2264 21 mmHg in both eyes at Screening Visit for patients with primary open-angle glaucoma or ocular hypertension (OHT). Patients with primary open-angle glaucoma or OHT were included provided they were on stable monotherapy bilaterally with IOP controlled (\u2264 21 mmHg) in both eyes. Any topical IOP-lowering medications must have had a start date of \u2265 3 months prior to Screening Visit date and dosage that was not expected to change during the study.",
        "criterionType": "Inclusion",
        "queryableStatus": "partially_queryable",
        "estimatedEliminationRate": 10.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": false,
        "funnelPriority": 36,
        "omopMappings": []
      },
      {
        "keyId": "KC013",
        "category": "safety_exclusion",
        "normalizedText": "Have uncontrolled severe systemic disease that, in the assessment of the investigator, would put safety of the participant at risk through participation, or which would prevent or confound protocol-specified assessments (e.g., hypertension and diabetes, Sj\u00f6gren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, immunodeficiency disease, etc.)",
        "criterionType": "Exclusion",
        "queryableStatus": "partially_queryable",
        "estimatedEliminationRate": 20.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": true,
        "funnelPriority": 51,
        "omopMappings": []
      },
      {
        "keyId": "KC023",
        "category": "safety_exclusion",
        "normalizedText": "Presence of 1 or more of the following ocular conditions in at least 1 eye:\n\n\u25cb Active ocular infection or non-keratoconjunctivitis sicca (KCS) ocular inflammation\n\n\u039f Active ocular allergy",
        "criterionType": "Exclusion",
        "queryableStatus": "partially_queryable",
        "estimatedEliminationRate": 15.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": true,
        "funnelPriority": 52,
        "omopMappings": []
      },
      {
        "keyId": "KC019",
        "category": "administrative",
        "normalizedText": "Patient anticipated contact lens wear during the study, or the patient had worn contact lenses in the last 3 months prior to Screening Visit",
        "criterionType": "Exclusion",
        "queryableStatus": "partially_queryable",
        "estimatedEliminationRate": 15.0,
        "requiresManualAssessment": true,
        "isKillerCriterion": true,
        "funnelPriority": 61,
        "omopMappings": []
      }
    ],
    "funnelStages": [
      {
        "stageName": "Disease Indication",
        "stageType": "disease_indication",
        "stageOrder": 1,
        "patientsEntering": 0,
        "patientsExiting": 0,
        "eliminationRate": 0.0,
        "cumulativeElimination": 0.0,
        "criteriaCount": 1
      },
      {
        "stageName": "Demographics",
        "stageType": "demographics",
        "stageOrder": 2,
        "patientsEntering": 0,
        "patientsExiting": 0,
        "eliminationRate": 0.0,
        "cumulativeElimination": 0.0,
        "criteriaCount": 1
      },
      {
        "stageName": "Treatment History",
        "stageType": "treatment_history",
        "stageOrder": 4,
        "patientsEntering": 0,
        "patientsExiting": 0,
        "eliminationRate": 0.0,
        "cumulativeElimination": 0.0,
        "criteriaCount": 4
      },
      {
        "stageName": "Lab Criteria",
        "stageType": "lab_criteria",
        "stageOrder": 6,
        "patientsEntering": 0,
        "patientsExiting": 0,
        "eliminationRate": 0.0,
        "cumulativeElimination": 0.0,
        "criteriaCount": 6
      },
      {
        "stageName": "Safety Exclusions",
        "stageType": "safety_exclusions",
        "stageOrder": 7,
        "patientsEntering": 0,
        "patientsExiting": 0,
        "eliminationRate": 0.0,
        "cumulativeElimination": 0.0,
        "criteriaCount": 3
      }
    ],
    "populationEstimates": {
      "initialPopulation": 1000000,
      "finalEligibleEstimate": 0,
      "confidenceInterval": {
        "low": 0,
        "high": 0
      },
      "estimationMethod": "deprecated_v1_funnel"
    },
    "killerCriteria": [
      "KC003",
      "KC031",
      "KC001",
      "KC022",
      "KC013",
      "KC023",
      "KC019",
      "KC029"
    ],
    "optimizationOpportunities": [],
    "manualAssessmentCriteria": [
      "KC002",
      "KC003",
      "KC004",
      "KC005",
      "KC006",
      "KC007",
      "KC008",
      "KC009",
      "KC011",
      "KC012",
      "KC013",
      "KC014",
      "KC015",
      "KC016",
      "KC017",
      "KC018",
      "KC019",
      "KC020",
      "KC021",
      "KC022",
      "KC023",
      "KC024",
      "KC025",
      "KC026",
      "KC028",
      "KC030",
      "KC031",
      "KC033"
    ],
    "siteRankings": [],
    "metadata": {
      "dataSource": "unknown",
      "dataQualityScore": 0.0,
      "estimationConfidence": "low",
      "executionTimeSeconds": 0.0,
      "stagesExecuted": 0,
      "totalCriteriaAnalyzed": 0,
      "overallEliminationRate": 100.0,
      "funnelEfficiencyScore": 62.5
    },
    "errors": [],
    "warnings": []
  },
  "summary": {
    "protocol_id": "NCT05878067",
    "total_criteria_analyzed": 33,
    "key_criteria_count": 15,
    "funnel_stages_count": 5,
    "initial_population": 1000000,
    "final_eligible_estimate": 0,
    "overall_elimination_rate": 100.0,
    "killer_criteria": [
      "KC003",
      "KC031",
      "KC001",
      "KC022",
      "KC013",
      "KC023",
      "KC019",
      "KC029"
    ],
    "manual_assessment_count": 28,
    "optimization_opportunities_count": 0
  },
  "classification_metadata": {
    "total_criteria": 33,
    "key_criteria_generated": 33,
    "category_distribution": {
      "primary_anchor": 2,
      "administrative": 7,
      "safety_exclusion": 10,
      "functional": 8,
      "treatment_history": 6
    },
    "queryability_distribution": {
      "fully_queryable": 5,
      "non_queryable": 13,
      "partially_queryable": 15
    },
    "model_used": "gemini-2.5-pro"
  }
}